CRISPR Therapeutics AG’s filing revealed that its Director George Simeon acquired Company’s shares for reported $51.5 million on Jul 16 ’25. In the deal valued at $52.03 per share,989,812 shares were bought. As a result of this transaction, George Simeon now holds 1,730,179 shares worth roughly $112.05 million.
Then, Patel Naimish sold 3,932 shares, generating $141,316 in total proceeds. Upon selling the shares at $35.94, the Chief Medical Officer now owns 6,068 shares.
Before that, Kulkarni Samarth sold 10,031 shares. CRISPR Therapeutics AG shares valued at $413,578 were divested by the Chief Executive Officer at a price of $41.23 per share. As a result of the transaction, Kulkarni Samarth now holds 195,085 shares, worth roughly $12.63 million.
Evercore ISI upgraded its CRISPR Therapeutics AG [CRSP] rating to an Outperform from a an In-line in a research note published on February 14, 2025; the price target was increased to $99 from $60. A number of analysts have revised their coverage, including TD Cowen’s analysts, who increased its forecast for the stock in mid February from “a Sell” to “a Hold”. H.C. Wainwright began covering CRSP with “Buy” recommendation on February 03, 2025. Needham maintained its rating on August 06, 2024. It rated CRSP as “a Buy”.
Price Performance Review of CRSP
On Friday, CRISPR Therapeutics AG [NASDAQ:CRSP] saw its stock fall -1.97% to $64.76. Over the last five days, the stock has lost -0.57%. CRISPR Therapeutics AG shares have risen nearly 13.24% since the year began. Nevertheless, the stocks have risen 64.53% over the past one year. While a 52-week high of $71.13 was reached on 07/21/25, a 52-week low of $30.04 was recorded on 04/07/25.
Levels Of Support And Resistance For CRSP Stock
The 24-hour chart illustrates a support level at 63.66, which if violated will result in even more drops to 62.55. On the upside, there is a resistance level at 66.62. A further resistance level may holdings at 68.47.
How much short interest is there in CRISPR Therapeutics AG?
A steep rise in short interest was recorded in CRISPR Therapeutics AG stocks on 2025-07-15, growing by 3.89 million shares to a total of 25.3 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-13 was 21.41 million shares. There was a rise of 15.36%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on August 02, 2024 when Rodman & Renshaw began covering the stock and recommended ‘”a Buy”‘ rating along with a $90 price target.
